Oncosil Medical Ltd (ASX:OSL) has announced that a patient with pancreatic cancer was able to reduce their tumor through treatment with the company’s eponymous device in conjunction with chemotherapy during a procedure in Türkiye.
Following successful treatment with the OncoSil device – together with chemotherapy – the patient’s tumor was reduced to a level which enabled surgical resection, and this surgery was carried out by Professor Dr. Koray Acarli, a renowned specialist in pancreatic cancer.
Oncosil noted that the successful treatment represented a milestone in proving the device’s efficacy within international markets, particularly when used alongside chemotherapy.
CEO & Managing Director Nigel Lange said he hoped this milestone would better facilitate the Oncosil device’s greater reach in other countries.
“We are thrilled to see the positive outcome from the first use of the OncoSil device in Türkiye,” he said.
“This achievement underscores the global potential of OncoSil to improve the lives of patients battling pancreatic cancer.
“We look forward to advancing our clinical program and bringing this innovative treatment option to more patients worldwide.”
Investors seemed happy with the news, and at 12:18 AEST, Oncosil shares were trading at 1.1 cents, a rise of 10% since the market opened.
